The Neuromuscular and Neurogenetic Disorders of Childhood Section (NNDCS) is dedicated to elucidating the genetic and pathophysiologic basis of early-onset neuromuscular disorders, to exploring therapeutic approaches to these conditions and to bringing first clinical trials to patients affected by these disorders. To accomplish these goals, we are using next generation genomic technology, tissue, cellular and animal models in the laboratory, while in the clinic we are using outcome measures and biomarker research, the development of phenotyping tools and novel trial designs to enable first clinical trials in patients. A particular focus in the section is on early onset muscle disorders caused by mutations in genes coding for components of the muscle extracellular matrix and its receptors (often falling within the group of Congenital Muscular Dystrophies, CMD) and on reducing body myopathy, a severe early onset myopathy with aggregate formation. For the matrix myopathies we will be studying the mechanisms of muscle involvement in mouse models, in particular as they relate to atrophy, failing regeneration and abnormal growth factor signaling in the muscle. A pathway independent approach directed at the causative mutation will be developed for dominant negative mutations in collagen VI. We also discovered a novel deep intronic mutation in COL6A1 causing inclusion of a dominant negative pseudo-exon and are developing a therapeutic approach to this mutation. In a clinical cohort of patients with the most common of the matrix CMDs (COL6 and LAMA2) we are now conduction a phase I pk study under sponsorship of Santhera pharmaceutical (Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO, NCT01805024). This trial is based on our careful natural history and clinical outcomes study. We are using next generation sequencing technology to identify new genes in our cohort of undiagnosed patients, including a novel syndrome of congenital muscular dystrophy with sensorineural deafness and a group of patients with collagen VI-like disorders, and a novel syndrome of PIEZO2 deficiency, leading to loss of proprioception and touch and significant musculoskeletal deformities. Finally, in collaboration with Dr Steven Gray at the University of North Carolina we are performing a first trial of intrathecal gene transfer in giant axonal neuropathy, using scAAV9/JeT-GAN, (Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy, NCT02362438). We are also participating in a study to define natural history and outcome measures in the congenital myopathy myotubular myopathy (A Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) Subjects (INCEPTUS, NCT02704273) in preparation for a gene transfer study in this condition, under the sponsorship of Audentes Therapsutics.

Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
2017
Total Cost
Indirect Cost
City
State
Country
Zip Code
Witherspoon, Jessica W; Vasavada, Ruhi P; Waite, Melissa R et al. (2018) 6-minute walk test as a measure of disease progression and fatigability in a cohort of individuals with RYR1-related myopathies. Orphanet J Rare Dis 13:105
Mohassel, Payam; Reghan Foley, A; Bönnemann, Carsten G (2018) Extracellular matrix-driven congenital muscular dystrophies. Matrix Biol 71-72:188-204
Sapp, Julie C; Johnston, Jennifer J; Driscoll, Kate et al. (2018) Evaluation of Recipients of Positive and Negative Secondary Findings Evaluations in a Hybrid CLIA-Research Sequencing Pilot. Am J Hum Genet 103:358-366
Gonorazky, Hernan D; Bönnemann, Carsten G; Dowling, James J (2018) The genetics of congenital myopathies. Handb Clin Neurol 148:549-564
Todd, Joshua J; Razaqyar, Muslima S; Witherspoon, Jessica W et al. (2018) Novel Variants in Individuals with RYR1-Related Congenital Myopathies: Genetic, Laboratory, and Clinical Findings. Front Neurol 9:118
Ortiz-González, Xilma R; Tintos-Hernández, Jesus A; Keller, Kierstin et al. (2018) Homozygous boricua TBCK mutation causes neurodegeneration and aberrant autophagy. Ann Neurol 83:153-165
Bönnemann, Carsten G (2018) Understanding Titin Variants in the Age of Next-Generation Sequencing-A Titanic Challenge. JAMA Neurol 75:539-540
Fan, Y; Liu, A; Wei, C et al. (2018) Genetic and clinical findings in a Chinese cohort of patients with collagen VI-related myopathies. Clin Genet 93:1159-1171
Dabaj, Ivana; Carlier, Robert Y; Gómez-Andrés, David et al. (2018) Clinical and imaging hallmarks of the MYH7-related myopathy with severe axial involvement. Muscle Nerve 58:224-234
Zaharieva, Irina T; Sarkozy, Anna; Munot, Pinki et al. (2018) STAC3 variants cause a congenital myopathy with distinctive dysmorphic features and malignant hyperthermia susceptibility. Hum Mutat 39:1980-1994

Showing the most recent 10 out of 113 publications